Why Early Matters: Data-Driven Strategies To De-Risk OSD Development

Late-stage formulation and manufacturing challenges continue to be a major source of cost, delays, and development risk in oral solid dosage (OSD) programs, particularly for complex and poorly soluble molecules. Too often, critical formulation, process, and manufacturability issues are identified only after significant time and resources have been invested.

In this on-demand webinar, Quentin Horgan, Director of Drugs Intelligence at GlobalData, joins Anil Kane, Senior Director of Global Technical & Scientific Affairs at Thermo Fisher Scientific, to discuss how early-stage insights can improve development outcomes and reduce downstream risk. The conversation explores how data-driven characterization, predictive modeling, and Quality by Design (QbD) principles can help teams identify potential challenges earlier, optimize formulation and process strategies, and make more informed decisions before scale-up begins.

Viewers will gain insights into why early development represents a critical opportunity to reduce cost, complexity, and late-stage surprises; how advanced data and predictive tools can minimize trial-and-error and support smarter decision-making; and what it takes to develop scalable OSD formulations that enable smoother technology transfer, scale-up, and commercialization. The webinar also examines key trends shaping the OSD landscape in 2026, including market growth, emerging technologies, and evolving opportunities across therapeutic areas.